Sun Pharmaceutical Industries Secures Crucial Approval for Semaglutide in Brazil
Sun Pharmaceutical Industries has secured a crucial approval from ANVISA to manufacture and market Semaglutide injection in Brazil for the treatment of adults with inadequately controlled type 2 diabetes mellitus. This approval marks Sun Pharma’s second international approval for Semaglutide, reflecting the strength of the company’s development and manufacturing capabilities.
